ITGAX and non-small cell lung carcinoma: This effort was supported by the formation of the IIT panel in predicting the response of NSCLC to ICB treatment (Figure 3C); the potential of ITGAL, ITGAX, and TMEM119 was further supported by their significant, albeit imperfect, correlations in both LUAD and LUSC (Table S3).